Caris Life Sciences (CAI) Common Equity (2024 - 2026)

Caris Life Sciences' Common Equity history runs 3 years deep, the most recent figure standing at $593.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 122.83% year-over-year to $593.5 million; the TTM figure through Mar 2026 stood at $593.5 million (up 122.83% YoY), while the FY2025 annual figure was $577.3 million, up 123.1% from the prior year.
• Common Equity was $593.5 million for Q1 2026 at Caris Life Sciences, up from $577.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $593.5 million in Q1 2026 to a low of -$2.6 billion in Q1 2025.
• Historically, Common Equity has averaged -$974.8 million across 3 years, with a median of -$953.3 million in 2024.
• Biggest YoY gain for Common Equity was 123.1% in 2025; the steepest drop was 119.19% in 2025.
• A 3-year view of Common Equity shows it stood at -$2.5 billion in 2024, then surged by 123.1% to $577.3 million in 2025, then gained by 2.8% to $593.5 million in 2026.
• The last three Common Equity figures came in at $593.5 million (Q1 2026), $577.3 million (Q4 2025), and $478.4 million (Q3 2025), per Business Quant data.